January 18th Biotech Update

Not the best start to the week but to be honest, it is not surprising that we get some weakness as we were stretched to the top of the trading range.  I still would not rule out of break this week but the chart probably needed to reset the overbought conditions in the near term.  […]

November 3rd Biotech Update

Guess what?  The Fed speaks and the market declines (along with the sector).  As I said the earnings season has been quite good for the sector but as I have also said one should not try and fight the Fed.  As long as the perception is higher rates for longer, then I do not see […]

September 8th Biotech Update

Sorry for the little break.  I am hopefully back and at it.  The sector has not done great but it does not look too bad either.  There have been lower lows and lower highs, which signals a clear downtrend but it seems to have been pretty orderly and we are now back to the old […]

May 24th Biotech Update

It was a good start to the week but the yo-yo continues.  I think if the broader market was not weak that the sector would be forming an uptrend.  For the first time in a long time it feels like the sector wants to outperform the broader market.  Our issue is that the broader market […]

March 9 Biotech (and Energy) Update

Has the market adjusted to the conflict in the Ukraine?  Commodities are cooling off, VIX is going down and risk assets (and the market) are going higher.  As I noted, I think the market decline has passed if the conflict does not expand or escalate.  The situation has been simmering at the current levels for […]

January 18th Biotech Update

So it looked really bad last Friday and it was quite the comeback rally.  Unfortunately it seems like the broader market is not looking very good and I cannot imagine a scenario with a broader market/risk off move and the sector somehow moves higher.  I guess one can never say never but it seems exceptionally […]

January 12th Biotech Update

I think the big news that was going to drop this week has dropped.  There are still a lot of companies I am going to be following up with so there is still plenty to write about but I do not big new news coming.  Given the lack of M&A and some negative news the […]

January 3rd Biotech Update

2021 is finally over and 2022 enters with hopes of a better year but we all are probably scarred from the year that was 2021.  JPM is coming and that brings with it hopes of M&A, positive guidance, and perhaps positive data.  Last year it was not great and that ended up being a signal […]

November 3nd Biotech Update

  The sector seems to be building some momentum (dare I say) but I guess it shows how low expectations were that two strong days in a row seems like such an accomplishment.  We did get a drug price proposal in the bills in congress but it is a win for the sector.  It allows […]

October 18th Biotech Update

Not a great start to the week both in terms of news and trading.  I think they are linked in that we had a series of bad news and that is impacting the sector.  I do not think any of the news runs the risk of forcing a downside break but certainly it was not […]

October 8th Biotech Update

The kids have their fall break so I am working from home but wanted to provide at least a couple of thoughts as there has been some news.  It will be very interesting to see if the sector keeps the positive momentum of yesterday after what seems to be significantly negative clinical news.  One might […]

October 4th Biotech Update

The sector is at an odd sort of place.  It seemed to catch a break and had a reversal off of some support late last week and today we are back to the selling.  It does not help that the broader market is not doing well either but at some point the sector has to […]

October 1st Biotech Update

The sector cannot catch a break as we get great clinical news this morning and it will likely end up hurting the sector more than helping.  The question in my mind now is whether the support for the sector is $122 or $118 ranges as one cannot ignore the selling in response to positive news.  […]

September 30th Biotech Update

What seemed like long rumored has come to pass with a decently sized deal in the sector.  The reaction yesterday was quite negative and I think expectations on price got too high.  I firmly believe that if this deal was announced last Monday (before the runup in XLRN started) at this exact same price the […]

April 5th Biotech Update

While it is possible that this week is decision week for the sector, I am not convinced that it has to be.  There is room above and below for it to tread water and not signal its next big move.  I see the $150 and $125 levels as the key ones to watch and the […]

November 15 Biotech Update

Today is an important day for the sector. We are at very long term support (the 200 week MA) that has rarely been breached (occasionally but never in a sustained manner). At levels that should provide some support we get some partnership news that is positive for SMID (it seems like partnerships are the new […]

Upcoming earnings and conferences this week

With the first quarter behind us, we look to updates across the biotech industry on new product launches and guidance for the year. We are also coming upon the summer medical conference series. Additionally, we briefly discuss 2 upcoming FDA approvals. Upcoming earnings releases and updates Monday, April 22nd After-Hours: ILMN Tuesday, April 23rd Pre-Market: […]

Biotech and Pharma earnings preview

Starting after-hours on Tuesday, we’ll see a lot of biotech and pharmaceuticals earnings, guidance, and outlook on their current programs. With the market cooling off, companies will be under pressure to meet investor expectations. Next week a number of sector leaders will kick things off. We’ve listed the updates in chronological order. Amgen (Nasdaq: AMGN) […]

An October full of data and decisions

With October underway, we felt the need to highlight some of the most important upcoming data readouts and regulatory decisions. This month is particularly busy on the regulatory side of things with 5 PDUFAs, 4 Advisory Committees, 6 FDA actions, and multiple potential European Medicines Agency(EMA) decisions. The events are listed in chronological order. Eli […]